Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
Recruiting · NCT06690970 · Observational (researchers observe without assigning treatment) · Lead sponsor: Tianjin Medical University
View the official record on ClinicalTrials.gov →Interventions studied
68Ga/18F-PSMA/PSFA
What this trial is about
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients (prostate cancer, hepatic cancer, etc.).
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion criteria
- \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where it is running
3 locations listed.
- The First Affiliated Hospital of University of Science and Technology of China - Hefei, Anhui, China
- The Affiliated Hospital of Qingdao University - Qingdao, Shandong, China
- Tianjin Medical University General Hospital - Tianjin, Tianjin Municipality, China